CRISPR and the Future of Human Genetic Medicine

CRISPR-Cas9 gene editing has progressed from a 2012 landmark paper to clinically approved therapies in just over a decade — one of the most rapid bench-to-bedside translations in biomedical history. The first CRISPR-based medicine, exagamglogene autotemcel (Casgevy), was approved in 2023 for sickle cell disease and transfusion-dependent beta-thalassemia, curing conditions that previously required lifelong management or bone marrow transplantation. We are at the beginning of a new era in genetic medicine.

How CRISPR-Cas9 Gene Editing Works

CRISPR-Cas9 consists of two components: a guide RNA (gRNA) engineered to match a specific 20-nucleotide DNA sequence in the target genome, and the Cas9 endonuclease protein that follows the gRNA to its target and cuts both DNA strands. The double-strand break is then repaired by the cell's DNA repair machinery — either through error-prone NHEJ (non-homologous end joining), which introduces small insertions or deletions that disrupt gene function, or through HDR (homology-directed repair) using a provided DNA template, which can insert specific sequences with precision.

Approved and Emerging Clinical Applications

Casgevy edits patients' hematopoietic stem cells ex vivo to reactivate fetal hemoglobin by disrupting the BCL11A erythroid enhancer. In clinical trials, virtually all patients with sickle cell disease achieved freedom from vaso-occlusive crises. NTLA-2001 (Intellia Therapeutics) delivers CRISPR in vivo via lipid nanoparticles to hepatocytes, disrupting the TTR gene and providing durable treatment for transthyretin amyloidosis. Base editors and prime editors — next-generation CRISPR tools that make precise single-base changes without double-strand breaks — are entering clinical trials for conditions including sickle cell disease, familial hypercholesterolemia, and hereditary angioedema.

Germline Editing and Ethical Boundaries

The 2018 announcement of the first gene-edited human babies (by He Jiankui, who edited CCR5 in embryos) triggered worldwide scientific condemnation and highlighted the absence of adequate governance frameworks for germline editing. Somatic gene editing — editing the cells of an individual patient — is broadly accepted as an extension of gene therapy. Germline editing — changing DNA in eggs, sperm, or embryos that would be inherited by all future descendants — raises qualitatively different ethical questions about consent, heritable effects, and equity that international scientific bodies have called for resolving before any clinical applications proceed. For more on how genetic variation shapes drug responses, see our companion article on pharmacogenomics and drug response.

For more information, visit our homepage or our resources section.